Kato T, Murata A, Ishida H, Toda H, Tanaka N, Hayashida H, Monden M, Matsuura N
Department of Surgery II, Osaka University Medical School, Japan.
Antimicrob Agents Chemother. 1995 Jun;39(6):1336-40. doi: 10.1128/AAC.39.6.1336.
Interleukin 10 (IL-10) is known to suppress the induction of proinflammatory cytokines such as tumor necrosis factor (TNF) and IL-1 and is itself induced by monocytes and macrophages during sepsis. We studied the therapeutic efficacy of IL-10 by testing its effect on the survival rate in the murine cecal ligation-and-puncture (CLP) model. Administration of 1 microgram or more of recombinant murine IL-10 6 h after induction of sepsis decreased lethality in septic mice significantly and also suppressed the elevation of circulating TNF after sepsis. However, treatment with the same dose of IL-10 simultaneously or 6 h before induction of CLP had no effect on survival, and treatment with anti-TNF antibody after induction of CLP had no effect on the survival rate. These data suggest that cytokine modulation with IL-10 is a potential candidate for the treatment of sepsis and sepsis-related multiple organ failure.
白细胞介素10（IL-10）已知可抑制促炎细胞因子如肿瘤坏死因子（TNF）和IL-1的诱导，并且在脓毒症期间其本身由单核细胞和巨噬细胞诱导产生。我们通过测试其对小鼠盲肠结扎穿刺（CLP）模型存活率的影响来研究IL-10的治疗效果。在脓毒症诱导后6小时给予1微克或更多的重组小鼠IL-10可显著降低脓毒症小鼠的致死率，并且还可抑制脓毒症后循环TNF的升高。然而，在CLP诱导前6小时或同时给予相同剂量的IL-10对存活率没有影响，并且在CLP诱导后用抗TNF抗体治疗对存活率也没有影响。这些数据表明，用IL-10进行细胞因子调节是治疗脓毒症和脓毒症相关多器官功能衰竭的潜在候选方法。
